The new single-use commercial facility will be among India’s largest, featuring advanced technologies to produce high-quality biologics and specialty pharmaceuticals
The portfolio includes foundational patents on the production, composition, and commercial use of NR
Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized
Under the agreement, AVT06 is licensed to enter the US market in the fourth quarter of 2026
This recognition demonstrate excellence in intellectual property (IP) value creation.
Hansoh Pharma will receive an upfront payment in the low double-digit millions
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
The study also showed a clear dose-dependent trend, with the 75 mg QD group outperforming the 50 mg QD cohort
Roche says its new assay “resolves this challenge by delivering accurate and specific results
Subscribe To Our Newsletter & Stay Updated
